A ground-breaking study by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has revealed crucial insights into the role of the histone methyltransferase NSD2 and its epigenetic target PKCα in causing t(4;14) translocated multiple myeloma (MM), a high-risk subtype of blood cancer, to be more aggressive and resistant to treatment.
CMS rolls out policy proposals on non-opioid drugs, radiopharmaceuticals — Lantheus stock jumps
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS